Interleukin-17 in transverse myelitis and multiple sclerosis

Journal of Neuroimmunology

Volumn 196, Issue 1-2, 2008, Pages 124-132

  Graber, Jerome J ^a,b   Allie, S Rameeza ^a   Mullen, Katherine M ^a   Jones, Melina V ^a   Wang, Tongguang ^a   Krishnan, Chitra ^a   Kaplin, Adam I ^c   Nath, Avi ^a   Kerr, Douglas A ^a   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Astrocytes; Interleukin 17; Interleukin 6; Multiple sclerosis; T cells; Transverse myelitis

Indexed keywords

CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 6;

ADULT; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

ADULT; ASTROCYTES; BRAIN; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETUS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INDOLES; INTERLEUKIN-16; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; MALE; MULTIPLE SCLEROSIS; MYELITIS, TRANSVERSE; NERVOUS SYSTEM DISEASES; TIME FACTORS;

EID: 44349141220     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.02.008     Document Type: Article

References (49)

1. Aggarwal S., Ghilardi N., Xie M.H., deSauvage F.J., and Gurney A.L. Interleukin 23 promotes a distinct CD4+ T cell activation state characterized by the production of interleukin 17. J. Biol. Chem. 278 (2003) 1910-1914
2. Andersson A., Kokkola R., Wefer J., Erlandsson-Harris H., and Harris R.A. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. J. Leukoc. Biol. 76 (2004) 1118-1124
3. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukaa M., Weiner H.L., and Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441 (2006) 235-238
4. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., and Oldstone M.B. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. PNAS 90 (1993) 10061-10065
5. Chauhan A., Turchan J., Pocernich C., Bruce-Keller A., Roth S., Butterfield D.A., and Nath A. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant site via axonal transport. J. Biol. Chem. 278 (2003) 13512-13519
6. Colombatti M., Moretto G., and Tommasi M. Human MBP-specific T cells regulate IL-6 gene expression in astrocytes through cell-cell contacts and soluble factors. Glia 35 (2001) 224-233
7. Constantinescu C.S., Tani M., and Ransahoff R.M. Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. J. Neurochem. 95 (2005) 331-340
8. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowsi M., Lira S.A., Kastelein R.A., and Sedgwick J.D. Interluekin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
9. de Seze J., Lanctin C., Lebrun C., Malikova I., Papeix C., Wiertlewski S., Pelletier J., Gout O., Clerc C., Moreau C., Defer G., Edan G., Dubas F., and Vermersch P. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 65 (2005) 1950-1953
10. Drakesmith H., O'Neil D., Schneider S.C., Binks M., Medd P., Sercarz E., Beverly P., and Chain B. In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. PNAS 95 (1998) 14903-14908
11. Duc Dodon M., Li Z., Hamaia S., and Gazzolo L. Tax protein of human T-cell leukaemia virus type 1 induces interleukin 17 gene expression in T cells. J. Gen. Virol. 85 (2004) 1921-1932
12. Frohman, E.M., Racke, M.K., Raine, C.S., Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med.;354:942-955.
13. Gijbels K., Brocke S., Abras J.S., and Steinman L. Administration of neutralizing antibodies to interleukin-6 reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med. 1 (1995) 795-805
14. Gran B., Zhang G.X., and Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. 23 (2004) 111-128
15. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., and Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11 (2005) 328-334
16. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., and Weaver C.T. Interleukin-17-producing CD4+ effect T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005) 1123-1132
17. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18 (2006) 349-356
18. Heppner F.L., Greter M., Marino D., Falsig J., Raivich G., Hovelmeyer N., Waisman A., Rulicke T., Prinz M., Priller J., Becher B., and Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005) 146-152
19. Hofman F.M., von Hanwehr R.I., Dinarello C.A., Mizel S.B., Hinton D., and Merrill J.E. Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J. Immunol. 136 (1986) 3239-3245
20. Hollifield R.D., Harbige L.S., Pham-Dinh D., and Sharief M.K. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36 (2003) 133-141
21. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumor necrosis factor-alpha therapy for rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63 (2004) 1538-1543
22. Infante-Duarte C., Horton H.F., Byrne M.C., and Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165 (2000) 6107-6115
23. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., and Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128 (2005) 988-1002
24. John G.R., Lee S.C., Song Z., Rivieccio M., and Brosnan C.F. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 49 (2005) 161-176
25. Jovanovic D.V., Di Battista J.A., and Marel-Pelletier J. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160 (1998) 3513-3521
26. Kaplin A.I., Deshpande D.M., Scott E., Krishnana C., Carmen J.S., Shats I., Martinez T., Drummond J., Dike S., Pletnikov M., Keswani S.C., Moran T.H., Pardo C.A., Calabresi P.A., and Kerr D.A. Interleukin 6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J. Clin. Invest. 10 (2005) 2731-2741
27. Kerr D.A., and Ayetey H. Immunopathogenesis of acute transverse myelitis. Curr Opin. Neurol. 15 (2002) 339-347
28. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., and Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 566-573
29. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanaghan T., Kastelstein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
30. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., and Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
31. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad A., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002) 500-508
32. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., and Weaver C.T. Transforming growth factor-β induces development of the Th17 lineage. Nature 441 (2006) 231-234
33. Matusevicius D., Kivisakk P., Kostulas N., Ozenci V., Fredrikson S., and Link H. Interluekin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5 (1999) 101-104
34. Michalopoulou M., Nikolaou C., and Tavernarakis A. Soluble interleukin-6 receptor in cerebrospinal fluid of patients with inflammatory and non-inflammatory neurologic diseases. Immunol. Lett. 94 (2004) 183-189
35. Miljkovic D.J., Drulovic J., Trajkovic V., Mesaros S., Dujmovic I., Maksimovic D., Samardzic T., Stojsavljevic N., Levic Z., and Mostarica Stojkovic M. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. Eur. J. Neurol. 9 (2002) 413-418
36. Okuda Y., Sakoda S., Bernard C.C., Fujimara H., Saeki Y., Kishimoto T., and Yanagihara T. IL-6 deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10 (1998) 703-708
37. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., Kamimura D., Ueda N., Iwakura Y., Ishihara K., Murakami M., and Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173 (2004) 3844-3854
38. Park H., Li Z., Yang X.O., Chan S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., and Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6 (2005) 1133-1141
39. Reder A.T., Kursad G., Byshosh P.V., and Porrini A.M. Monocyte activation in multiple sclerosis. Mult. Scler. 4 (1998) 162-168
40. Sharief M.K., and Henges R. Assocation between tumor necrosis factor-α and disease progression in multiple sclerosis. N. Engl. J. Med. 325 (1991) 467-472
41. Takahashi J.L., Giuliani F., Power C., Imai Y., and Yong V.W. Interleukine-1β promotes oligodendrocyte death through glutamate excitotoxicity. Ann. Neurol. 53 (2003) 588-595
42. Tilgner J., Volk B., and Kaltschmidt C. Continuous interleukin-6 application in vivo via macroencapsulation of interleukin-6-expressing COS-7 cells induces massive gliosis. Glia 35 (2001) 234-245
43. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 59 (2002) 499-505
44. Van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Bloberg B.M., Woody J.N., Hartung H.P., and Polman C.H. Increased MRI and clinical activity in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
45. Van Wagoner N.J., and Benveniste E.N. Interleukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 100 (1999) 124-139
46. Van Wagoner N.J., Oh J., Repovic P., and Benveniste E.N. Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J. Neurosci. 19 (1999) 5236-5244
47. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stocking B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
48. Wiendl H., and Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16 (2002) 183-200
49. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., and Achong M.K. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101 (1998) 311-320